Security
IMDX · Insight Molecular Diagnostics Inc.
IMDXNASDAQCommon stockCurrentCIK 1642380Updated Sep 26, 2026
Name history
OncoCyte Corp · through Jun 17, 2025Oncocyte Corp · through Jun 17, 2025
IMDX price & chart
Loading TradingView…
NASDAQ:IMDX on TradingView ↗In the news
Favorable Medicare Coverage Decision Supports Commercial Adoption of iMDx GraftAssure Assay Portfolio ↗
Seeking Alpha
Insight Molecular Diagnostics Inc. (IMDX) Discusses Advances in Heart Transplant Rejection Testing and Evolution of Diagnostic Methods Transcript ↗
Insight Molecular Diagnostics signals ~$8M quarterly cash burn in H2 2026 while targeting FDA authorization later this year ↗
Insight Molecular Diagnostics Inc. (IMDX) Q2 2026 Earnings Call Transcript ↗
Recent filings
Entry into a Material Definitive Agreement
Items 1.01, 9.01
10-Q filing
Results of Operations and Financial Condition · Regulation FD Disclosure · Other Events
Items 2.02, 7.01, 8.01, 9.01
S-8 filing
4 filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 25,756,000Source | 35,081,000Source | 74,892,000Source | 100,091,000Source |
| Property, Plant and Equipment, NetUSD | 9,250,000Source | 5,984,000Source | 4,710,000Source | 8,711,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 0Source | 14,607,000Source | 56,595,000Source | 61,633,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 11,583,000Source | 8,636,000Source | 9,432,000Source | 19,993,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 1,128,000Source | 1,613,000Source | 484,000Source | 2,012,000Source |
| Inventory, NetUSD | 446,000Source | 410,000Source | — | — |
| Assets, CurrentUSD | 15,306,000Source | 11,759,000Source | 10,698,000Source | 25,536,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,420,000Source | 821,000Source | 643,000Source | 977,000Source |
| Operating Lease, Right-of-Use AssetUSD | — | — | — | 3,499,000Source |
| Other Assets, NoncurrentUSD | 593,000Source | 691,000Source | 463,000Source | 371,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 57,220,000Source | 47,355,000Source | 49,298,000Source | 60,497,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | — | — | — |
| Common Stock, Value, IssuedUSD | 369,211,000Source | 338,244,000Source | 310,295,000Source | 294,929,000Source |
| Retained Earnings (Accumulated Deficit)USD | -400,761,000Source | -350,539,000Source | -289,876,000Source | -260,676,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 86,000Source | 21,000Source | 49,000Source | 39,000Source |
| Stockholders' Equity Attributable to ParentUSD | -31,464,000Source | -12,274,000Source | 20,468,000Source | 34,292,000Source |
| Liabilities and EquityUSD | 25,756,000Source | 35,081,000Source | 74,892,000Source | 100,091,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 12,075,000Source | 7,275,000Source | 7,194,000Source | 12,106,000Source |
| Accounts Payable, CurrentUSD | 2,544,000Source | 2,279,000Source | 953,000Source | 1,253,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 2,461,000Source | 1,939,000Source | 1,649,000Source | 1,771,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 2,197,000Source | 1,564,000Source | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 2,219,000Source | 1,753,000Source | 2,760,000Source | 10,042,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | -485,000Source | 1,129,000Source | -109,000Source | 575,000Source |
| Increase (Decrease) in InventoriesUSD | 36,000Source | 410,000Source | — | — |
| Deferred Income Tax Expense (Benefit)USD | — | — | 0Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -22,184,000Source | -20,713,000Source | -23,325,000Source | -45,568,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -3,185,000Source | -512,000Source | -932,000Source | -4,340,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 3,185,000Source | 516,000Source | 281,000Source | 4,340,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 72,000Source | — | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 28,072,000Source | 20,429,000Source | 12,186,000Source | 35,806,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 2,583,000Source | -796,000Source | -12,071,000Source | -14,102,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | 23,203,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 91,000Source | 42,000Source | — | 24,000Source |
| Income Taxes Paid, NetUSD | 0Source | — | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 2,219,000Source | 1,753,000Source | 2,760,000Source | 10,042,000Source |
| Amortization of Debt Issuance CostsUSD | — | — | — | 12,000Source |
| Amortization of Intangible AssetsUSD | 7,000Source | 88,000Source | 88,000Source | 3,692,000Source |
| DepreciationUSD | — | — | — | 1,528,000Source |
| Disposal Group, Not Discontinued Operation, Gain (Loss) on DisposalUSD | — | — | -1,521,000Source | — |
| Foreign Currency Transaction Gain (Loss), UnrealizedUSD | -185,000Source | — | — | — |
| Gain (Loss) on Disposition of AssetsUSD | 0Source | -169,000Source | -1,283,000Source | — |
| Gain (Loss) on Disposition of Other AssetsUSD | 0Source | -169,000Source | -1,283,000Source | — |
| General and Administrative ExpenseUSD | 10,633,000Source | 10,204,000Source | 11,182,000Source | 21,881,000Source |
| Goodwill, Impairment LossUSD | — | — | — | 18,684,000Source |
| Impairment of Intangible Assets, Finite-livedUSD | 14,600,000Source | 41,900,000Source | 6,757,000Source | — |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | -50,222,000Source | -60,663,000Source | — | -18,612,000Source |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | -2,926,000Source | -54,290,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | — | — |
| Inventory Write-downUSD | — | — | 139,000Source | — |
| Marketable Securities, Gain (Loss), Excluding Other-than-temporary Impairment LossUSD | — | 0Source | -61,000Source | — |
| Marketable Securities, Unrealized Gain (Loss)USD | — | — | — | -471,000Source |
| Net Income (Loss) Attributable to ParentUSD | -50,222,000Source | -60,663,000Source | -27,781,000Source | -72,902,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -50,222,000Source | -60,926,000Source | -28,723,000Source | -73,422,000Source |
| Nonoperating Income (Expense)USD | 902,000Source | 378,000Source | 281,000Source | -615,000Source |
| Operating ExpensesUSD | 53,422,000Source | 61,781,000Source | 25,549,000Source | 17,979,000Source |
| Other Nonoperating Income (Expense)USD | 1,011,000Source | 462,000Source | 394,000Source | -67,000Source |
| Proceeds from Issuance of Common StockUSD | 29,143,000Source | 26,012,000Source | 13,848,000Source | 32,812,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 4,055,000Source | 1,881,000Source | 1,503,000Source | 958,000Source |
| Cost of Goods and Services Sold | — | — | — | — |
| Operating Income (Loss)USD | -51,124,000Source | -61,041,000Source | -25,136,000Source | -17,997,000Source |
| Other Nonoperating Income (Expense)USD | 1,011,000Source | 462,000Source | 394,000Source | -67,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | -60,663,000Source | -24,855,000Source | -18,612,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -50,222,000Source | -60,663,000Source | -27,781,000Source | -72,902,000Source |
| Earnings Per Share, BasicUSD per share | -1.65Source | -4.66Source | -3.75Source | -0.66Source |
| Earnings Per Share, DilutedUSD per share | -1.65Source | -4.66Source | -3.75Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 30,476,000Source | 13,071,000Source | 7,651,000Source | 110,800Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 30,476,000Source | 13,071,000Source | 7,651,000Source | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 7,000Source | 88,000Source | 88,000Source | 3,692,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | 2,190,000Source | 1,476,000Source | 1,592,000Source | 1,500,000Source |
| General and Administrative ExpenseUSD | 10,633,000Source | 10,204,000Source | 11,182,000Source | 21,881,000Source |
| Goodwill, Impairment LossUSD | — | — | — | 18,684,000Source |
| Gross ProfitUSD | 2,298,000Source | 740,000Source | 413,000Source | -18,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | -50,222,000Source | -60,663,000Source | — | -18,612,000Source |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | — | -4.66Source | -3.37Source | -0.17Source |
| Income (Loss) from Continuing Operations, Per Diluted ShareUSD per share | — | -4.66Source | -3.37Source | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | -2,926,000Source | -54,290,000Source |
| Interest Income (Expense), NetUSD | -109,000Source | -84,000Source | -52,000Source | -77,000Source |
| Marketing and Advertising ExpenseUSD | 582,000Source | 257,000Source | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -50,222,000Source | -60,926,000Source | -28,723,000Source | -73,422,000Source |
| Net Income (Loss) from Continuing Operations Available to Common Shareholders, BasicUSD | — | -60,926,000Source | -25,797,000Source | — |
| Nonoperating Income (Expense)USD | 902,000Source | 378,000Source | 281,000Source | -615,000Source |
| Operating ExpensesUSD | 53,422,000Source | 61,781,000Source | 25,549,000Source | 17,979,000Source |
| Research and Development ExpenseUSD | 15,900,000Source | 9,839,000Source | 9,294,000Source | 7,301,000Source |
| Selling and Marketing ExpenseUSD | 6,343,000Source | 3,944,000Source | 2,795,000Source | 1,132,000Source |
Filing attachments
ex99-1.htm · 8-K · 2026-08-10
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 IMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDx Discussions with FDA advance toward expected marketing authorization for GraftAssureDx FDA completes current portion of substantive review in a timely manner Favorable Medicare reimbursement policy issued in July significantly increases GraftAssureDx surveillance testing opportunity Strong head-to-head data drive kitted customer interest N…
Read attachment ↗ex99-1.htm · 8-K · 2026-05-13
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 IMDX Reports Q1 2026 Results and Update on Progress Toward GraftAssure Commercialization Progressing toward commercialization with third-party head-to-head data publications and GALACTIC registry study engagement Northeast kidney transplant center (among the top 10 in the U.S.) is first to sign clinical trial agreement to participate in GALACTIC study Booked research-use-only purchase by E.U. transplant center and APAC purchase expected…
Read attachment ↗ex99-1.htm · 8-K · 2026-03-26
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 IMDX Submits GraftAssureDx for FDA Review and Reports Q4 2025 Results Submitted GraftAssureDxTM for kidney transplant rejection testing for FDA review on Wednesday, March 25 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── Welcomed second favorable head-to-head data set from an independent study at large hospital comparing GraftAssure to a leading centra…
Read attachment ↗